Key breakthroughs in small molecule MYC inhibitors.
作者信息
Dhimitriu Rafaelo, Tsimpili Helena, Zoidis Grigoris
机构信息
Division of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
出版信息
Future Med Chem. 2025 May;17(10):1097-1100. doi: 10.1080/17568919.2025.2504325. Epub 2025 May 12.
Abstract
摘要
相似文献
1
Key breakthroughs in small molecule MYC inhibitors.小分子MYC抑制剂的关键突破。
Future Med Chem. 2025 May;17(10):1097-1100. doi: 10.1080/17568919.2025.2504325. Epub 2025 May 12.
2
Molecular heterogeneity and MYC dysregulation in triple-negative breast cancer: genomic advances and therapeutic implications.三阴性乳腺癌中的分子异质性与MYC失调：基因组学进展及治疗意义
3 Biotech. 2025 Jan;15(1):33. doi: 10.1007/s13205-024-04195-0. Epub 2025 Jan 5.
3
Developing MYC Degraders Bearing the Von Hippel-Lindau Ligand to Target the "Undruggable" MYC.开发携带冯·希佩尔-林道配体的MYC降解剂以靶向“不可成药”的MYC。
ACS Pharmacol Transl Sci. 2024 Nov 15;7(12):3955-3968. doi: 10.1021/acsptsci.4c00452. eCollection 2024 Dec 13.
4
Targeted Disruption of Myc-Max Oncoprotein Complex by a Small Molecule.小分子对Myc-Max癌蛋白复合物的靶向破坏
ACS Chem Biol. 2017 Nov 17;12(11):2715-2719. doi: 10.1021/acschembio.7b00799. Epub 2017 Oct 11.
5
Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.计算机辅助药物发现 Myc-Max 抑制剂作为治疗前列腺癌的潜在疗法。
Eur J Med Chem. 2018 Dec 5;160:108-119. doi: 10.1016/j.ejmech.2018.09.023. Epub 2018 Sep 11.
6
Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.与整合素靶向纳米颗粒偶联的小分子MYC抑制剂可延长播散性多发性骨髓瘤小鼠模型的生存期。
Mol Cancer Ther. 2015 Jun;14(6):1286-1294. doi: 10.1158/1535-7163.MCT-14-0774-T. Epub 2015 Mar 30.
7
MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer.MYC 与 IIa 类组蛋白去乙酰化酶抑制共同作用会导致非小细胞肺癌中的线粒体功能障碍。
Cell Rep. 2025 Jun 24;44(6):115722. doi: 10.1016/j.celrep.2025.115722. Epub 2025 May 19.
8
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.新型小分子 c-Myc/Max 二聚体抑制剂 10074-G5 的体外细胞毒性和体内疗效、药代动力学和代谢。
J Pharmacol Exp Ther. 2010 Dec;335(3):715-27. doi: 10.1124/jpet.110.170555. Epub 2010 Aug 26.
9
A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors.一种基于表面等离子体共振的定量方法，用于评估c-Myc癌蛋白与DNA的结合以及小分子抑制剂对其结合的破坏作用。
J Biol Methods. 2015;2(2). doi: 10.14440/jbm.2015.54.
10
Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5.利用小分子10074-G5的改良细胞穿透类似物破坏Myc-Max异二聚化。
Oncotarget. 2013 Jun;4(6):936-47. doi: 10.18632/oncotarget.1108.
本文引用的文献
1
MYC-Targeting PROTACs Lead to Bimodal Degradation and N-Terminal Truncation.靶向MYC的PROTAC导致双峰降解和N端截短。
ACS Chem Biol. 2025 Apr 18;20(4):896-906. doi: 10.1021/acschembio.4c00864. Epub 2025 Mar 27.
2
Beyond small molecules: advancing MYC-targeted cancer therapies through protein engineering.超越小分子：通过蛋白质工程推进针对MYC的癌症治疗。
Transcription. 2025 Feb;16(1):67-85. doi: 10.1080/21541264.2025.2453315. Epub 2025 Jan 29.
3
Design, Synthesis, and Biological Evaluation of Thieno[3,2-]pyrimidine Derivatives as the First Bifunctional PI3Kδ Isoform Selective/Bromodomain and Extra-Terminal Inhibitors.噻吩并[3,2 - ]嘧啶衍生物作为首个双功能PI3Kδ亚型选择性/溴结构域和额外末端抑制剂的设计、合成及生物学评价
J Med Chem. 2025 Feb 13;68(3):3260-3281. doi: 10.1021/acs.jmedchem.4c02478. Epub 2025 Jan 24.
4
Repurposing of phosphodiesterase-5 inhibitor sildenafil as a therapeutic agent to prevent gastric cancer growth through suppressing c-MYC stability for IL-6 transcription.磷酸二酯酶-5抑制剂西地那非的重新利用作为一种治疗剂，通过抑制白细胞介素-6转录的c-MYC稳定性来预防胃癌生长。
Commun Biol. 2025 Jan 18;8(1):85. doi: 10.1038/s42003-025-07519-9.
5
Discovery of 4,5-dihydro-benzo[g]indazole-based hydroxamic acids as HDAC3/BRD4 dual inhibitors and anti-tumor agents.发现基于4,5-二氢苯并[g]吲唑的异羟肟酸作为HDAC3/BRD4双重抑制剂和抗肿瘤剂。
Eur J Med Chem. 2025 Mar 5;285:117230. doi: 10.1016/j.ejmech.2024.117230. Epub 2024 Dec 30.
6
Developing MYC Degraders Bearing the Von Hippel-Lindau Ligand to Target the "Undruggable" MYC.开发携带冯·希佩尔-林道配体的MYC降解剂以靶向“不可成药”的MYC。
ACS Pharmacol Transl Sci. 2024 Nov 15;7(12):3955-3968. doi: 10.1021/acsptsci.4c00452. eCollection 2024 Dec 13.
7
Discovery of 4-(4-(3-(1-(2-(piperidin-1-yl)ethyl)-1H-benzo[d]imidazole-2-yl)isoxazol-5-yl)phenyl)morpholine as a novel c-Myc inhibitor against lung cancer in vitro and in vivo.发现 4-(4-(3-(1-(2-(哌啶-1-基)乙基)-1H-苯并[d]咪唑-2-基)异噁唑-5-基)苯基)吗啉作为一种新型的 c-Myc 抑制剂，用于体外和体内肺癌的治疗。
Eur J Med Chem. 2025 Jan 5;281:117023. doi: 10.1016/j.ejmech.2024.117023. Epub 2024 Nov 7.
8
GRP78 inhibitor YUM70 upregulates 4E-BP1 and suppresses c-MYC expression and viability of oncogenic c-MYC tumors.GRP78 抑制剂 YUM70 上调 4E-BP1 并抑制致癌 c-MYC 肿瘤的 c-MYC 表达和活力。
Neoplasia. 2024 Sep;55:101020. doi: 10.1016/j.neo.2024.101020. Epub 2024 Jul 10.
9
Directly Suppressing MYC Function with Novel Alkynyl-Substituted Phenylpyrazole Derivatives that Induce Protein Degradation and Perturb MYC/MAX Interaction.用新型炔基取代的苯基吡唑衍生物直接抑制MYC功能，该衍生物可诱导蛋白质降解并扰乱MYC/MAX相互作用。
J Med Chem. 2024 Jul 25;67(14):11751-11768. doi: 10.1021/acs.jmedchem.4c00272. Epub 2024 Jul 11.
10
Design, synthesis, and activity evaluation of 2-iminobenzimidazoles as c-Myc inhibitors for treating multiple myeloma.作为治疗多发性骨髓瘤的c-Myc抑制剂的2-亚氨基苯并咪唑的设计、合成及活性评价
Heliyon. 2024 Mar 26;10(7):e28411. doi: 10.1016/j.heliyon.2024.e28411. eCollection 2024 Apr 15.
Zotero 插件